Comparison between urinary pyridinium cross-links and hydroxylysine glycosides in monitoring the effects of ovariectomy and 17 beta-estradiol replacement in aged rats.
This study was undertaken to assess the sensitivity of hydroxylysylpyridinoline (HP), lysylpyridinoline (LP), galactosylhydroxylysine (GHyl) and glucosylgalactosylhydroxylysine (GGHyl) to monitor bone response to estrogen deficiency and replacement by comparing their excretory patterns in ovariectomized aged (11-14 months old) rats. The ovariectomized (OVX) rats were randomized into two groups: (1) OVX plus vehicle; (2) OVX plus 17 beta-estradiol (17-beta E, 10 micrograms/kg, s.c., 4 days/week). Treatment with 17-beta E started immediately after OVX and continued for 60 days. The collagen catabolites were measured in urine for 1 month before OVX and thereafter for 60 days. In temporal coincidence with urine collection, bone area and bone mineral density (BMD) of lumbar vertebrae, femoral diaphysis and distal metaphysis were measured by dual-energy X-ray absorptiometry. In the untreated rats, BMD of the femoral metaphysis and lumbar vertebrae decreased significantly and the urinary excretion of LP, HP, GHyl and GGHyl increased with different patterns. In the treated rats, 17-beta E replacement prevented the increment in LP excretion, partially prevented the increase in HP excretion, but had no effect on the excretion of GHyl and GGHyl. In conclusion pyridinolines and glycosides have different sensitivities to the bone response to OVX. Glycoside excretion after OVX also reflects metabolic processes not strictly related to bone loss and, in contrast with LP, is not sensitive to estrogen replacement.
Pecile
A
A
Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milano, Italy.
Netti
C
C
Sibilia
V
V
Villa
I
I
Calori
G
G
Tenni
R
R
Coluzzi
M
M
Moro
G L
GL
Rubinacci
A
A
D015502:Absorptiometry, Photon; D000596:Amino Acids / Q000652:urine; D000818:Animals; D015415:Biomarkers / Q000652:urine; D001842:Bone and Bones / Q000378:metabolism; D004958:Estradiol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006901:Hydroxylysine / Q000031:analogs & derivatives* / Q000652:urine; D010052:Ovariectomy; D011726:Pyridinium Compounds / Q000652:urine*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D000596:Amino Acids; D015415:Biomarkers; D011726:Pyridinium Compounds; C022819:hydroxylysine glycoside; D006901:Hydroxylysine; C001295:glucosylgalactosylhydroxylysine; C007817:galactosylhydroxylysine; D004958:Estradiol; C015484:pyridinoline; C036020:deoxypyridinoline